Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
Open Access
- 26 October 2021
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 9 (10), e003395
- https://doi.org/10.1136/jitc-2021-003395
Abstract
Background In melanoma patients who progress after prior ipilimumab/nivolumab (ipi/nivo) combination immunotherapy, there is no information regarding the risks and benefits of reinduction ipi/nivo. Methods This was a retrospective review of 26 melanoma patients treated at Memorial Sloan Kettering Cancer Center (MSKCC) since 2012 who received reinduction ipi/nivo at least 6 months following completion of an initial course of ipi/nivo. We collected data on demographics, genetics, immune-related adverse events (irAEs), best overall responses (BORs), time to treatment failure (TTF) and overall survival (OS). Results The BOR rate (complete response+partial response) was 74% (95% CI 52% to 90%) after the first course of ipi/nivo but only 23% (95% CI 8% to 45%)) after reinduction. Response to reinduction did not correlate with response to the initial course. Among the 16 patients who had an objective response to the first course, only four (25%) responded to reinduction. Of five patients who did not respond to the first course, one responded to reinduction. For all patients, median TTF was 5.3 months after reinduction; TTF was shorter for reinduction than for the first course in 85% of patients. Median OS from reinduction was 8.4 months; estimated 2-year OS was 18%. Although reinduction was associated with fewer irAEs than the initial course of ipi/nivo (58% of patients vs 85% of patients in the initial course), eight (31%) patients experienced at least one new irAE after the second course. Conclusions BOR rate and TTF were markedly less favorable after reinduction with ipi/nivo than after the initial course of ipi/nivo. Reinduction ipi/nivo was associated with frequent irAEs although less frequent than for the initial course.Funding Information
- Bristol-Myers Squibb
- National Cancer Institute (P30-CA008748)
This publication has 21 references indexed in Scilit:
- Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaThe New England Journal of Medicine, 2016
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaThe New England Journal of Medicine, 2015
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studiesAnnals of Oncology, 2014
- Genetic Evolution of T-cell Resistance in the Course of Melanoma ProgressionClinical Cancer Research, 2014
- Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in ItalyBritish Journal of Cancer, 2014
- Nivolumab plus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2013
- Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease ControlClinical Cancer Research, 2013
- Loss of Functional Beta2-Microglobulin in Metastatic Melanomas From Five Patients Receiving ImmunotherapyJNCI Journal of the National Cancer Institute, 1996
- Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression.JCI Insight, 1991